MYD88 and diffuse large B-cell lymphoma: Primary OA-DLBCL-NOS frequently exhibited pathogenic variants in MYD88 (4 of 14, 29%), CD79B (3 of 14, 21%), PIM1 (3 of 14, 21%), TBL1XR1 (3 of 14, 21%), SETD1B (3 of 14, 21%), and DUSP2 (3 of 14, 21%) (Figure 2).